Why Scientists Are Turning Skin Cells Into Nerve Cells
Studying human disease can begin with a basic problem: researchers need the right cells. Making specialized cells in a laboratory can help them investigate disease and test possible medicines. The NIH’s stem cell overview explains why these research tools matter, even before any treatment reaches patients. On October 22, 2026, UCLA reported a new approach […]
REPROCELL Wins MSCRF Award to Advance Hypoimmune iPSC Platforms
What happens when cell therapy needs to reach more patients, but manufacturing and immune compatibility still act like locked gates? That is the tension behind REPROCELL’s new Commercialization Award from the Maryland Stem Cell Research Fund, which will support work on hypoimmune iPSC platforms for clinical applications.1 This is not a flashy promise about a […]
Gene-Edited Stem Cell Transplants for Aggressive Blood Cancers: What the New Trial Shows
New trial data show how gene-edited stem cell transplants may help aggressive AML and MDS treatment.
Rewind Your Biological Clock: Gene & Stem Cell Secrets with Dr. Adeel Khan
Aging—it’s something we all face, but what if science could slow it down, or even reverse it? Dr. Adeel Khan, a leading expert in regenerative medicine, recently joined the Mindvalley Podcast to shed light on the cutting-edge advancements in stem cell therapy and gene editing. If you’ve ever wondered whether we’re on the brink of […]
Accelerating Heart Disease Research: Allen Institute’s New Disease-Specific Cell Lines
On June 4, 2024, the Allen Institute for Cell Science announced the launch of its first disease-specific cell line collections, marking a significant milestone in genetic heart disease research. This innovative set of tools, specifically designed to advance the study of hypertrophic cardiomyopathy (HCM) and other muscle disorders, represents a groundbreaking step in the quest […]
Pioneering Medical Breakthrough: Mouse Lungs Successfully Grown in Rats
In a world-first, researchers at the Phoenix Children’s Research Institute, part of the University of Arizona College of Medicine — Phoenix, have achieved a significant medical milestone that could pave the way for groundbreaking treatments of lung diseases. This innovative research marks a crucial step toward the potential of creating human lungs using large animals […]
CRISPR Therapeutics’ FDA Approval for CASGEVY™
CRISPR Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving CASGEVY™ (exagamglogene autotemcel [exa-cel]), a groundbreaking CRISPR/Cas9 gene-edited cell therapy. This approval makes CASGEVY available for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older. Approximately 1,000 patients in the U.S. are now eligible for […]
RoslinCT and the Revolutionary CRISPR-Based Gene Therapy CASGEVY™
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has achieved a groundbreaking milestone in the field of medical science. Building on its legacy since the cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has now been entrusted with the manufacturing of the first-ever U.S. Food and […]
RoslinCT Unveils CRISPR: A Medical Revolution Begins
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant advancement in the field of medical science. They will be manufacturing the world’s first CRISPR-based therapy, exa-cel, for Vertex Pharmaceuticals Inc. This development follows an extensive collaboration between the two entities. Key Highlights: About RoslinCT: RoslinCT has a […]
RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy
RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]